Perspective Therapeutics, Inc. (CATX)

Price, with every insider trade on it

Closing prices, 12 months · point at a dot for who traded, or at the line for the close

2.66 on 9 Oct 2026

2 buys7 sales at will0 planned sales

Key numbers

Fiscal year 2023, ended 31 Dec 2023, as filed

Revenue

$1.43M

Net income

$46.51M

Free cash flow

$37.99M

Gross margin

100.0%

Operating margin

-2,855.0%

Net margin

-3,243.2%

Return on equity

-61.9%

Return on capital

-42.1%

Debt to equity

0.02

Revenue growth, 5 yr

-27.8% a year

Revenue and profit

Fiscal years, as filed with the SEC · point at a year for the detail

Full statements →

RevenueNet incomeLoss

Latest insider transactions

From Form 4, most recent first

All of them →

Date	Insider	Type	Value	Of own stake
4 Sep 2026	Lantheus Alpha Therapy, LLC 10% owner	Sold at will	$526.05K	1.5%
3 Sep 2026	Lantheus Alpha Therapy, LLC 10% owner	Sold at will	$250.90K	0.7%
2 Sep 2026	Lantheus Alpha Therapy, LLC 10% owner	Sold at will	$131.22K	0.4%
1 Sep 2026	Lantheus Alpha Therapy, LLC 10% owner	Sold at will	$111.57K	0.3%
1 Sep 2026	Lantheus Holdings, Inc. 10% owner	Sold at will	$111.57K	0.3%
31 Aug 2026	Lantheus Alpha Therapy, LLC 10% owner	Sold at will	$245.61K	0.7%

Clue Score

How it works

35out of 100

Profitability 0

Financial strength 80

Growth 0

Insiders 77

Strongest on financial strength (80), weakest on growth (0). A score of the business, not of the price.

What insiders did

Last 12 months

Only here

Bought

$42.24K

2 buys, 2 buyers

Sold

$1.62M

7 sales

Planned sales

under a 10b5-1 plan

Every insider, every trade →

Profile

Sector: Health care
Industry: Pharmaceutical Preparations
Country: United States
SEC filings: EDGAR →